Oncology

GSK
Pharma

GSK talks through Hibsago launch as it reports out mixed Q3

Armed with a trio of recent high-profile approvals, GSK is banking on its specialty medicines to drive its next wave of growth.
Fraiser Kansteiner Oct 28, 2026 11:05am
radiopharmaceutical radiopharmaceuticals nuclear medicine radiopharma targeted alpha therapy

Radiopharmaceutical player NorthStar locks up $185M

Sep 30, 2026 9:00am
Daniel ODay
Favicon Fierce Biotech

CEO O’Day tells Fierce how Gilead reached ‘critical mass’

Sep 16, 2026 8:00am
Revolution Medicines booth at ASCO 2026

FDA greenlights RevMed’s pancreatic cancer gamechanger

Aug 26, 2026 11:30am
Connection together puzzle pieces Concept of business strategy collaboration

McKesson acquires Maryland CRO for $2.25 billion

Aug 25, 2026 11:22am
Daiichi

Daiichi promotes Ken Keller to lead new commercialization unit

Aug 24, 2026 4:32am
More News

Karyopharm reports Xpovio miss, FDA filing in separate cancers

Jul 31, 2026 10:00am
Fierce Biotech

How India can build on its budding innovative R&D moment: report

Jul 23, 2026 5:00am

Roche tops cancer reputation rankings as AstraZeneca climbs back

Jul 2, 2026 6:00am

FDA finds fault with Pinnacle’s photodynamic therapy videos

Jun 25, 2026 10:12am